All In Biotech

Drug Trial Radar · NCT03705234

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 16,124 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

16,124

Actual

Start

Oct 30, 2018

Primary completion

Oct 2026

Study completion Dec 2049

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The TIMI Study Group; Novartis Pharmaceuticals
First posted
Oct 15, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ORION-4 is a research study coordinated by the University of Oxford and co-sponsored by The University of Oxford and Novartis (Protocol: CTSU\_MDCO-PCS-17-01 (CKJX839B12301)). The study aims to find out if a new cholesterol-lowering injection (inclisiran) safely lowers the risk of heart attacks and strokes in people who have already had one of these conditions, or who have had an operation or procedure to treat blocked arteries.

Conditions

  • Atherosclerotic Cardiovascular Disease

Interventions

  • InclisiranDrug

    Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.

  • PlaceboDrug

    Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with a major adverse cardiovascular event (MACE)Time frame: Median follow-up of 5-years

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • TIMI Study Group

    Boston, Massachusetts

  • CTSU, University of Oxford

    Oxford, Oxfordshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.